Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives

References

• Martini A, Lovell DJ, Albani S, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):5. doi:10.1038/s41572-021-00332-8
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057
   PubMed Web of Science ®Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–1551, 1551 e1. doi:10.1016/j.ophtha.2009.05.002
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Del Giudice E, Swart JF, Wulffraat NM. Juvenile idiopathic arthritis. In: El Miedany Y, editor. Comorbidity in Rheumatic Diseases. Springer International Publishing. 2017:265–288.
   Google Scholar
• Haasnoot AM, Kuiper JJ, Hiddingh S, et al. Ocular fluid analysis in children reveals interleukin-29/interferon-λ1 as a biomarker for juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2016;68(7):1769–1779. doi:10.1002/art.39621
   PubMed Web of Science ®Google Scholar
• Kolomeyer AM, Crane ES, Tu Y, Liu D, Chu DS. Adult patients with uveitis associated with juvenile idiopathic arthritis: a retrospective review. Can J Ophthalmol. 2017;52(5):458–462. doi:10.1016/j.jcjo.2017.01.011
   PubMed Web of Science ®Google Scholar
• Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76(4):383–388. doi:10.1016/j.jbspin.2008.10.015
   PubMed Web of Science ®Google Scholar
• Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016;14(1):27. doi:10.1186/s12969-016-0088-2
   PubMed Web of Science ®Google Scholar
• Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52(3):826–832. doi:10.1002/art.20945
   PubMed Web of Science ®Google Scholar
• Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120(1):186–192. doi:10.1016/j.ophtha.2012.07.052
   PubMed Web of Science ®Google Scholar
• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi:10.1016/j.ophtha.2009.12.003
   PubMed Web of Science ®Google Scholar
• Paroli MP, Abbouda A, Restivo L, Sapia A, Abicca I, Pivetti Pezzi P. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm. 2015;23(1):74–81. doi:10.3109/09273948.2013.855798
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology. 2013;52(5):825–831. doi:10.1093/rheumatology/kes186
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, McCracken C, Yeh S, et al. Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis. Pediatr Rheumatol Online J. 2015;13:19. doi:10.1186/s12969-015-0018-8
   PubMed Web of Science ®Google Scholar
• Grassi A, Corona F, Casellato A, Carnelli V, Bardare M. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. J Rheumatol. 2007;34(5):1139–1145.
   PubMed Web of Science ®Google Scholar
• Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol. 2015;160(1):193–200 e1. doi:10.1016/j.ajo.2015.04.016
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32(5):1121–1133. doi:10.1007/s00296-011-2126-1
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019;71(6):864–877. doi:10.1002/art.40885
   PubMed Web of Science ®Google Scholar
• Bou R, Adan A, Borras F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785. doi:10.1007/s00296-015-3231-3
   PubMed Web of Science ®Google Scholar
• Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138–150. doi:10.1097/ICU.0000000000000562
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2):180–184. doi:10.1136/bjo.2006.094698
   PubMed Web of Science ®Google Scholar
• Goebel JC, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–213. doi:10.1136/bjo.2009.173542
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998;82(7):737–742. doi:10.1136/bjo.82.7.737
   PubMed Web of Science ®Google Scholar
• Yu EN, Meniconi ME, Tufail F, Baltatzis S, Foster CS, Christen WG. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm. 2005;13(5):353–360. doi:10.1080/09273940590951061
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. doi:10.1002/art.20904
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of Adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14. doi:10.1186/1745-6215-15-14
   PubMed Web of Science ®Google Scholar
• Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res. 2014;66(7):1073–1084. doi:10.1002/acr.22214
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117. doi:10.1136/annrheumdis-2018-213131
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of Adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011. doi:10.1136/annrheumdis-2017-212089
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of Adalimumab versus infliximab. Arthritis Care Res. 2011;63(4):612–618. doi:10.1002/acr.20404
   PubMed Web of Science ®Google Scholar
• Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and Adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi:10.3899/jrheum.120583
   PubMed Web of Science ®Google Scholar
• Li Y, Mao X, Tang X, Mao H. Efficacy and safety of anti-TNFalpha therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatol Ther. 2021;8(2):711–727. doi:10.1007/s40744-021-00296-x
   PubMed Web of Science ®Google Scholar
• Verstegen RHJ, McMillan R, Feldman BM, Ito S, Laxer RM. Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review. Rheumatology. 2020;59(2):386–397. doi:10.1093/rheumatology/kez285
   PubMed Web of Science ®Google Scholar
• Wakefield D, Clarke D, McCluskey P. Recent developments in HLA B27 anterior uveitis. Front Immunol. 2020;11:608134. doi:10.3389/fimmu.2020.608134
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80. doi:10.1016/j.ajo.2017.08.019
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675. doi:10.1002/art.39940
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi:10.1016/S2665-9913(20)30008-4
   PubMedGoogle Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391. doi:10.1016/S0140-6736(08)60998-8
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35(9):1897–1898.
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297–300. doi:10.1007/s00417-010-1523-6
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010;62(6):821–825. doi:10.1002/acr.20115
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50(8):1390–1394. doi:10.1093/rheumatology/ker107
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. doi:10.1136/annrheumdis-2017-211555
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. doi:10.1038/nrd.2017.267
   PubMed Web of Science ®Google Scholar
• Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi:10.1016/j.clim.2019.108322
   PubMed Web of Science ®Google Scholar
• Bing SJ, Lyu C, Xu B, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis. 2020;26:641–651.
   PubMed Web of Science ®Google Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. doi:10.1080/09273948.2019.1605453
   PubMed Web of Science ®Google Scholar
• Dipasquale V, Atteritano M, Fresta J, Castagna I, Conti G. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a report of two cases. J Clin Pharm Ther. 2019;44(3):482–485. doi:10.1111/jcpt.12821
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–55. doi:10.1016/j.ajoc.2018.12.001
   PubMedGoogle Scholar
• Tappeiner C, Mesquida M, Adan A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183–2188. doi:10.3899/jrheum.160231
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Giuffre C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi:10.1007/s10067-019-04875-w
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, Adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi:10.1186/s13063-021-05651-5
   PubMed Web of Science ®Google Scholar
• Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Suppl 2):ii24–ii30. doi:10.1093/rheumatology/keaa895
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(5):320. doi:10.1038/nrrheum.2017.51
   PubMed Web of Science ®Google Scholar
• Del Giudice E, Simio C, Scala A, et al. Juvenile idiopathic arthritis-associated uveitis in the era of biological therapy: how the disease changed in more than 20 years of observation in a tertiary referral center in Rome (Italy). Int Ophthalmol. 2022;42(3):775–784. doi:10.1007/s10792-021-02043-1
   PubMed Web of Science ®Google Scholar